In addition, HNF4 alpha, a novel transcriptional inhibitor of SELENBP1, plays a role in prostate cancer by binding to the SELENBP1 promoter region (Elhodaky et al., 2020). This evidence concerns the gene SELENBP1 and prostate carcinoma.